Form HealthvsPlushCare Weight Loss

Form Health is a telehealth obesity clinic, not a drug itself. After an online intake, you are matched with a care team led by an ABOM-certified obesity-medicine physician (or advanced practice provider) plus a registered dietitian. They review your history and, when medically appropriate, prescribe FDA-approved anti-obesity medications such as Wegovy (semaglutide), Zepbound (tirzepatide), Saxenda (liraglutide), or Contrave. Most of these are GLP-1-based drugs that mimic gut hormones to slow stomach emptying, reduce appetite, and curb cravings (tirzepatide also acts on the GIP receptor). Care is delivered through video visits, unlimited messaging, and an app for weight and food tracking, combining medication with nutrition and behavior change.

PlushCare itself is a telehealth platform, not a drug. You book a video visit with a board-certified physician who reviews your history, orders an obesity lab panel (typically CBC, a metabolic panel, lipids, A1C, TSH, and insulin, drawn through a lab such as Quest), and, if appropriate, prescribes a GLP-1 medication sent to your pharmacy. The medications work by mimicking gut hormones: semaglutide (Wegovy/Ozempic) activates GLP-1 receptors, while tirzepatide (Zepbound/Mounjaro) activates both GLP-1 and GIP receptors. They slow stomach emptying, reduce appetite, and increase fullness, so you tend to eat less and lose weight.

Form Health reports an average of 16% body-weight loss at 18 months across its patients (with and without medication), but this is the company's own internal program data, not an independently published, peer-reviewed clinical trial, so treat it as a marketing claim rather than proof. The medications Form prescribes do have strong trial evidence. In the STEP-1 trial (NEJM, 2021), adults on weekly semaglutide 2.4 mg (Wegovy) lost an average of about 14.9% of body weight at 68 weeks versus 2.4% on placebo. In SURMOUNT-1 (NEJM, 2022), tirzepatide (Zepbound) produced average losses of roughly 15% to 21% over 72 weeks depending on dose (about 15.0% at 5 mg up to 20.9% at 15 mg in the primary analysis, and higher, up to about 22.5%, among adherent participants). Real-world telehealth outcomes are often somewhat lower than trial figures because of drug discontinuation and adherence.

PlushCare does not run its own trials; efficacy comes from the medications it prescribes. In the STEP 1 trial (NEJM 2021, 1,961 adults without diabetes), once-weekly semaglutide 2.4 mg (Wegovy) produced a mean 14.9% body-weight loss at 68 weeks versus 2.4% for placebo, with about 50.5% of users losing at least 15% of their body weight. In the SURMOUNT-1 trial (NEJM 2022, 2,539 adults), tirzepatide (Zepbound) produced mean reductions of about 16.0%, 21.4%, and 22.5% at the 5 mg, 10 mg, and 15 mg doses over 72 weeks, versus roughly 2.4% for placebo. Results depend on reaching and staying on an effective dose, and weight tends to return if the medication is stopped. Compounded versions are not FDA-approved and have not been tested for the same bioequivalence, so results with them may differ.

Side effects come from the prescribed medication, not the service itself. The most common with GLP-1 drugs (Wegovy, Zepbound, Saxenda) are gastrointestinal: nausea, diarrhea, vomiting, constipation, and abdominal discomfort, usually mild-to-moderate and worst during dose escalation. Contrave can cause nausea, headache, constipation, insomnia, and raised blood pressure. Serious but uncommon risks include acute pancreatitis, gallbladder disease, and kidney injury from dehydration. GLP-1 drugs carry an FDA boxed warning for thyroid C-cell tumors seen in rodents and are contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2. Seek prompt medical care for severe, persistent abdominal pain.

The side effects are those of the GLP-1 drugs themselves, not the platform. The most common are gastrointestinal: nausea, vomiting, diarrhea, constipation, and bloating, usually worst when starting or increasing the dose and often easing over time. Less common but serious risks include pancreatitis, gallbladder problems (including gallstones), and dehydration-related kidney injury from severe vomiting. These drugs carry an FDA boxed warning about thyroid C-cell tumors seen in rodents (the relevance to humans is unconfirmed, but they are contraindicated with a history of MTC or MEN 2). Tell your PlushCare doctor about severe or persistent abdominal pain, which can signal pancreatitis, and seek urgent care if it is intense.

As of 2026, Form Health's self-pay membership is about $299/month, which is HSA/FSA-eligible and covers physician and dietitian visits, messaging, and the app, but not medications or lab work. GLP-1 drugs can cost roughly $500 to $1,300 or more per month at cash price (manufacturer savings programs and lower-cost direct-pay vials for Wegovy and Zepbound can reduce this). Alternatively, Form can bill visits, labs, and medications through most major private insurance plans, in which case you pay only copays and deductibles, which can dramatically lower total cost. Medicare is more limited: by federal law it does not cover a drug prescribed solely for weight loss, so a GLP-1 is generally covered only when prescribed for a separate approved indication such as type 2 diabetes or cardiovascular risk reduction. Coverage varies widely by plan, so verify your specific benefits in writing before starting.

As of 2026, PlushCare charges a membership of about $19.99/month (often with a free first month) or roughly $99/year, plus consultation fees: about $129 per visit without insurance, or a copay (often $30 or less) with in-network insurance. These fees cover only the platform and doctor; the medication is billed separately. Brand-name GLP-1s can reach roughly $1,000+ per month at full retail if insurance denies coverage, but PlushCare also advertises promotional cash-pay brand pricing at times (for example, Ozempic and Wegovy near $199/month for the first two months, then higher) and offers compounded semaglutide in eligible states at around $149/month for the lowest dose and about $299/month for higher doses, which is paid out of pocket and does not run through insurance. PlushCare can attempt prior authorization for brand drugs, but GLP-1 coverage is never guaranteed and the process can take up to about two weeks. Confirm current pricing at signup, since promotional rates change.

Form Health is for US adults 18 and older with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as type 2 diabetes, high blood pressure, or high cholesterol. You must have a primary care provider and have seen them within the past 12 months, since Form coordinates with (rather than replaces) your PCP. It is not appropriate for people seeking treatment for an eating disorder, those who are pregnant or breastfeeding, or anyone with contraindications to the prescribed medication. GLP-1 drugs like Wegovy and Zepbound are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Always disclose your full medical history; the prescribing physician makes the final call.

PlushCare's program is for US adults who medically qualify for a GLP-1: generally a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, high cholesterol, or type 2 diabetes. These drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and should not be used by people with a prior serious reaction to them. They are not recommended in pregnancy or breastfeeding, and people with a history of pancreatitis, gallbladder disease, gastroparesis or other severe GI disorders, diabetic retinopathy, or significant kidney impairment need careful physician evaluation. Final eligibility is decided by the prescribing doctor, not automatically.